HALO Halozyme Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HALO

Price (delayed)

$108.17

Market cap

$12.28B

P/E Ratio

30.38

Dividend/share

N/A

EPS

$3.56

Enterprise value

$14.26B

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 92

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE ® drug delivery technology with the ...

Highlights
The company's revenue rose by 41% YoY and by 10% QoQ
HALO's gross profit is up by 38% YoY and by 10% QoQ
HALO's net income is down by 26% year-on-year but it is up by 19% since the previous quarter
HALO's EPS is down by 21% year-on-year but it is up by 20% since the previous quarter
Halozyme Therapeutics's quick ratio has plunged by 69% YoY and by 7% from the previous quarter
The company's equity has shrunk by 57% YoY and by 35% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.halozyme.com
Peers: MNKD LLY BAX PFE

Key stats

What are the main financial stats of HALO

HALO stock price

How has the Halozyme Therapeutics stock price performed over time
Intraday
1.93%
1 week
9.64%
1 month
37.62%
1 year
51.05%
YTD
60.73%
QTD
38.2%

Financial performance

How have Halozyme Therapeutics's revenue and profit performed over time
Revenue
$1.66B
Gross profit
$1.37B
Operating income
$597.2M
Net income
$413.6M
Gross margin
82.4%
Net margin
24.9%
The net margin has contracted by 47% YoY but it has grown by 8% from the previous quarter
The company's revenue rose by 41% YoY and by 10% QoQ
HALO's gross profit is up by 38% YoY and by 10% QoQ
The operating margin has declined by 38% year-on-year but it is up by 6% since the previous quarter

Price vs fundamentals

How does HALO's price correlate with its fundamentals

Growth

What is Halozyme Therapeutics's growth rate over time

Valuation

What is Halozyme Therapeutics stock price valuation
HALO P/E details
P/E
30.38
P/B
89.38
P/S
7.62
EV/EBIT
23.62
EV/EBITDA
19.85
EV/Sales
8.57
The stock's price to earnings (P/E) is 56% more than its 5-year quarterly average of 19.5 and 44% more than its last 4 quarters average of 21.1
HALO's EPS is down by 21% year-on-year but it is up by 20% since the previous quarter
HALO's price to book (P/B) is 129% higher than its 5-year quarterly average of 39.0 and 28% higher than its last 4 quarters average of 69.6
The company's equity has shrunk by 57% YoY and by 35% QoQ
The company's revenue rose by 41% YoY and by 10% QoQ
The price to sales (P/S) is 31% higher than the last 4 quarters average of 5.8 but 4.8% lower than the 5-year quarterly average of 8.0

Efficiency

How efficient is Halozyme Therapeutics business performance
The ROE has grown by 43% from the previous quarter and by 32% YoY
HALO's return on sales is down by 40% year-on-year but it is up by 4.9% since the previous quarter
Halozyme Therapeutics's return on assets has decreased by 38% YoY but it has increased by 12% QoQ
HALO's return on invested capital is up by 14% since the previous quarter but it is down by 12% year-on-year

Dividends

What is HALO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HALO.

Financial health

How did Halozyme Therapeutics financials performed over time
The company's total assets is 6% higher than its total liabilities
Halozyme Therapeutics's quick ratio has plunged by 69% YoY and by 7% from the previous quarter
The company's current ratio has shrunk by 68% YoY
The company's equity has shrunk by 57% YoY and by 35% QoQ
Halozyme Therapeutics's debt to equity has soared by 53% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.